| Identification | Back Directory | [Name]
Rosmantuzumab | [CAS]
1684393-04-1 | [Synonyms]
Rosmantuzumab
Rosmantuzumab (anti-RSPO3)
Research Grade Rosmantuzumab (DHJ51101) |
| Hazard Information | Back Directory | [Uses]
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors[1]. | [in vivo]
Rosmantuzumab (25 mg/kg; i.p., once a week for 4 weeks) significantly protects the animals from developing liver fibrosis[1].
Rosmantuzumab (25 mg/kg; i.p., once for two weeks, for total 6 weeks) significantly inhibits skin thickness, collagen deposition, and number of α-SMA positive cells in bleomycin-induced lung fibrosis mouse models[1]. | Animal Model: | Male C57B1/6J CCl4 liver fibrosis mouse models[1] | | Dosage: | 25 mg/kg | | Administration: | Intraperitoneal injection; 25 mg/kg, once a week for 4 weeks | | Result: | Significantly decreased collagen I and collagen III mRNAs, and inhibits β-catenin cytoplasmic and nuclear translocation.
|
| [References]
[1] Zhang M, et al. Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS One. 2020 Mar 11;15(3):e0229445. DOI:10.1371/journal.pone.0229445 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
|